Drug General Information
Drug ID
D08POF
Former ID
DCL000036
Drug Name
ALX-0081
Indication Thrombocytopenia [ICD9: 287.3, 287.4, 287.5; ICD10:D69.6, P61.0] Phase 2 [532188]
Company
Ablynx
Target and Pathway
Target(s) Von Willebrand factor Target Info Binder [550615]
KEGG Pathway PI3K-Akt signaling pathway
Focal adhesion
ECM-receptor interaction
Complement and coagulation cascades
Platelet activation
PANTHER Pathway Blood coagulation
Inflammation mediated by chemokine and cytokine signaling pathway
Reactome Platelet degranulation
Intrinsic Pathway of Fibrin Clot Formation
Integrin cell surface interactions
Integrin alphaIIb beta3 signaling
GRB2:SOS provides linkage to MAPK signaling for Integrins
p130Cas linkage to MAPK signaling for integrins
GP1b-IX-V activation signalling
MAP2K and MAPK activation
Platelet Adhesion to exposed collagen
WikiPathways Complement and Coagulation Cascades
Focal Adhesion
Blood Clotting Cascade
Platelet Adhesion to exposed collagen
Integrin alphaIIb beta3 signaling
GP1b-IX-V activation signalling
Formation of Fibrin Clot (Clotting Cascade)
References
Ref 532188Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor. J Cardiovasc Transl Res. 2013 Jun;6(3):355-63.
Ref 550615Clinical pipeline report, company report or official report of Ablynx

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.